Lenvatininb as Treatment for Naïve Patients with Aggressive Thyroid Cancer Bone Metastases and Bad Performance Status

Lenvatinib is an oral multityrosine kinase inhibitor (TKI) with proven effectiveness in the treatment of radioactive iodine- (RAI-) refractory and/or unresectable differentiated thyroid carcinoma (DTC). The present study reports the case of a 41-year-old male who underwent hemithyroidectomy in June...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Rodriguez, Sonia, Pinillos, Guillermo Martinez, Chaves-Conde, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292976/
https://www.ncbi.nlm.nih.gov/pubmed/32566339
http://dx.doi.org/10.1155/2020/8679149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292976/
https://www.ncbi.nlm.nih.gov/pubmed/32566339
http://dx.doi.org/10.1155/2020/8679149

Ejemplares similares